CN118221816A - Lag3单克隆抗体及其应用 - Google Patents
Lag3单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN118221816A CN118221816A CN202410287305.9A CN202410287305A CN118221816A CN 118221816 A CN118221816 A CN 118221816A CN 202410287305 A CN202410287305 A CN 202410287305A CN 118221816 A CN118221816 A CN 118221816A
- Authority
- CN
- China
- Prior art keywords
- antibody
- chain variable
- variable region
- seq
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 title claims abstract description 44
- 102000017578 LAG3 Human genes 0.000 title claims abstract description 42
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims abstract description 8
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 29
- 229940127121 immunoconjugate Drugs 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 11
- 239000012636 effector Substances 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101150036449 SIRPA gene Proteins 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108090001008 Avidin Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 102100036352 Protein disulfide-isomerase Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000002331 protein detection Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 230000000903 blocking effect Effects 0.000 abstract description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 6
- 239000003446 ligand Substances 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 35
- 150000001413 amino acids Chemical group 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000011161 development Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102100038664 Fibrinogen-like protein 1 Human genes 0.000 description 6
- 101001031635 Homo sapiens Fibrinogen-like protein 1 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 5
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- -1 etc.) Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101100510618 Homo sapiens LAG3 gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 102000043279 ADAM17 Human genes 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100028666 C-type lectin domain family 4 member G Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 101001136701 Dictyostelium discoideum Prespore-specific protein E Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102000000802 Galectin 3 Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000766915 Homo sapiens C-type lectin domain family 4 member G Proteins 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000005091 electrochemiluminescent agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229940121484 relatlimab Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供了多个能高亲和力地识别淋巴细胞激活基因3(LAG3)的单克隆抗体。所述抗体不仅亲和力高,而且能够阻断LAG3蛋白和其配体MHC‑II或FGL1的结合。本发明所提供的中和性单克隆抗体不仅具有良好的体外阻断活性,而且具有非常强的热稳定性,能够在体外促进PBMC细胞增殖和细胞因子释放,增强双特异性抗体和CAR‑T的肿瘤杀伤活性。
Description
技术领域
本发明属于生物技术领域,具体涉及识别LAG3的高亲和力单克隆抗体及其应用。
背景技术
淋巴细胞激活基因3(LAG3,CD223)是免疫球蛋白超家族的一员,是T细胞表面的一种重要的负调控因子。1990年LAG3在激活的NK细胞和T细胞上被发现,它包含4个胞外IgSF结构域和1个跨膜结构域以及1个胞内结构域,它在D4结构域和跨膜域中间可以通过蛋白酶ADAM10和ADAM17切割变为分泌型sLAG3。此外LAG3在DC细胞,B细胞,肿瘤浸润淋巴细胞,NK细胞,调节性T细胞,耗竭的CD8+T细胞等细胞上都检测到有表达。
在基因结构上LAG3同MHC-II有着大约20%的同源性,同时相比CD4蛋白,LAG3同MHC-II有着更高的亲和力。但是与CD4不同的是CD4主要表达在细胞表面,而LAG3却有很大一部分在胞内,当抗原刺激后LAG3迅速的转移到细胞表面行使功能。T细表面的LAG3分子上调表达引起了T细胞增殖的下调,由于LAG3同MHC-II分子亲和力相比CD4更高,同时通过抗体阻断LAG3同MHC-II相互作用可以显著的增强T细胞活性,因此过去普遍认为LAG3下调T细胞活性是通过和MHC-II分子相互作用。但是近年来发现一些针对LAG3同时不阻断其与MHC-II结合的抗体仍有一定的抗肿瘤活性,因此LAG3可能存在其他的配体来行使功能其中就包括Galectin-3,LSECtin,FGL1等。2019年《Cell》上的一篇文章表明FGL1可能也是的LAG3的主要抑制性配体(Fibrinogen-like Protein 1Is a Major Immune Inhibitory Ligandof LAG3,Wang J,et al,Cell,2019;176:334-347)。通过制备抗体阻断LAG3-MHC-II或LAG3-FGL1的相互作用,是肿瘤免疫治疗过程中的一种新策略。
发明内容
本发明的目的在于提供高亲和力识别LAG3的单克隆抗体。所提供的抗体包括抗体片段(例如单链可变区片段(scFv))和效应分子(例如毒素蛋白)的免疫缀合物。还提供了包括特异性结合LAG3的抗体的组合物、编码这些抗体的核酸分子、包含所述核酸分子的表达载体以及表达所述核酸分子的分离的宿主细胞。
本发明具体技术方案如下:
一种淋巴细胞激活基因3的单克隆抗体或其抗原结合片段,包括重链可变区和轻链可变区,所述单克隆抗体或其抗原结合片段包括SEQ ID NO:1所示的重链可变区CDR1、SEQ ID NO:2所示的重链可变区CDR2、SEQ ID NO:3所示的重链可变区CDR3,SEQ ID NO:4所示的轻链可变区CDR1、SEQ ID NO:5所示的轻链可变区CDR2、SEQ ID NO:6所示的轻链可变区CDR3。
人LAG3有三种已知的亚型(亚型1-3)。LAG3的三种亚型的核酸和氨基酸序列是已知的,包括GenBank登录号:NM_002286.6和NP_002277.4(亚型1);NM_001414176.1和NP_001401105.1(亚型2);NM_001414177.14和NP_001401106.1(亚型3)。本发明所述的抗体可结合所述三种人LAG3亚型的一种或多种,或其保守变体。
具体的,本发明所述的LAG3的抗体或其抗原结合片段为:
(1)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:7所示,轻链可变区氨基酸序列如SEQ ID NO:8所示;
或者,(2)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:9所示,轻链可变区氨基酸序列如SEQ ID NO:10所示。
或者,(3)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:11所示,轻链可变区氨基酸序列如SEQ ID NO:12所示。
或者,(4)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:13所示,轻链可变区氨基酸序列如SEQ ID NO:14所示。
或者,(5)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:15所示,轻链可变区氨基酸序列如SEQ ID NO:16所示。
本发明所述抗体是单链抗体、双链抗体、单克隆抗体或嵌合抗体。
本发明所述的单克隆抗体可以为任何同种型。可以为例如IgM或IgG抗体,例如IgG1或IgG2。可特异性结合LAG3的抗体的种类可根据已知的方法彼此转换(例如,IgG可转换为IgM)。种类转换还可用于使一种IgG亚类转换成另一亚类,例如从IgG1转换成IgG2。
本发明所述的抗体可以为:
(1)Fab,包含抗体分子的单价抗原结合片段的片段,其可以通过用木瓜蛋白酶消化完整抗体以产生完整轻链和一条重链的一部分而产生;
(2)Fab',可以通过用胃蛋白酶处理完整抗体、之后进行还原以产生完整轻链和重链的一部分而获得的抗体分子片段;每个抗体分子得到两个Fab'片段;
(3)(Fab')2,可以通过将完整的抗体用胃蛋白酶处理、但之后不进行还原而得到的抗体片段;F(ab')2是两个Fab'片段通过两个二硫键连接在一起的二聚体;
(4)Fv,含有表达为2条链的轻链可变区和重链可变区的基因程片段;
(5)单链抗体(例如scFv),含有轻链可变区和重链可变区并通过合适的多肽接头将其连接为遗传上融合的单链分子的基因工程分子;
(6)单链抗体的二聚体(scFv2),定义为scFv的二聚体(还被称为“微型抗体”);
(7)VH单结构域抗体,由重链可变区组成的抗体片段。
本领域技术人员会了解,可以制备抗体的保守变体。可以在所述VH和/或VL区进行氨基酸置换(例如1个、2个、3个、4个或5个氨基酸置换),置换后的VH和VL仍然保留结合LAG3的能力,或者对LAG3的结合能力更强。功能类似的氨基酸的保守置换是本领域普通技术人员所熟知的。以下六组是被认为是互为保守置换的氨基酸的实例:
1)丙氨酸(A)、丝氨酸(S)、苏氨酸(T);
2)天冬氨酸(D)、谷氨酸(E);
3)天冬酰胺(N)、谷氨酰胺(Q);
4)精氨酸(R)、赖氨酸(K);
5)异亮氨酸(I)、亮氨酸(L)、甲硫氨酸(M)、缬氨酸(V);
6)苯丙氨酸(F)、酪氨酸(Y)、色氨酸(W)。
本发明另一目的在于提供一种重组蛋白,所述的重组蛋白包括本发明所述的抗体或其抗原结合片段和协助表达和/或纯化的标签序列。所述的标签序列包括但不限于6xHis标签。
本发明另一目的在于公开本发明所述的单克隆抗体或抗原结合片段、双特异性抗体或融合蛋白、免疫偶联物、核酸分子在制备免疫检查点抑制剂中的应用。所述免疫检查点抑制剂为诊断或治疗自身免疫疾病、慢性病再感染或肿瘤的约物。所述的肿瘤为非霍奇金淋巴瘤、慢性淋巴细胞白血病、霍奇金氏病、实体瘤或转移瘤。
本发明所述可检测的标记物是可以被同位素分析仪、酶标仪、生物发光检测仪、化学发光检测仪、电化学发光检测仪、荧光分析仪器检测,或裸眼可视化的物质,这些物质包括但不限于放射性同位素(如3H、14C、15N、35S、90Y、、99Tc、111In、125I、131I)、可用于检测的酶类(如辣根过氧化物酶、β-半乳糖苷酶、碱性磷酸酶、葡萄糖氧化酶等)、荧光蛋白(如绿色荧光蛋白(GFP)、黄色荧光蛋白(YFP)、别藻蓝蛋白APC、藻红蛋白PE)、生物发光标记物(如萤光素酶)、荧光化合物(如荧光素、异硫氰酸荧光素、罗丹明、5-二甲基氨基-1-萘磺酰氯、藻红蛋白、荧光染料Cy3、Cy5、稀土无机发光材料、量子点等)、生物素、磁性试剂(例如钆)、电化学发光试剂(如三联吡啶钌)、胶体金。
效应分子可使用本领域技术人员已知的任何方式连接至本发明所述的抗体。例如,所述抗体可以被功能性地连接(通过化学偶联、基因融合、非共价缔合或其它)到一种或多种其他分子实体。根据效应分子的化学结构,连接所述效应分子和抗体的方法有所不同。多肽一般含有多个官能团;例如羧酸(COOH)、游离氨基(-NH2)或巯基(-SH),其可用于与抗体上合适的官能团发生反应以与所述效应分子结合。或者,可将所述抗体衍生化以暴露或连接另外的反应性官能团。所述衍生化可包括连接任意的多种已知接头分子。所述接头可以是用于接合所述抗体与效应分子的任何分子。所述接头能够与所述抗体和效应分子形成共价键。合适的接头对于本领域技术人员是熟知的,包括但不限于直链或支链的碳接头、杂环碳接头或肽接头。在所述抗体和效应分子是多肽的情况下,所述接头可以通过其侧基(例如通过半胱氨酸的二硫键)接合到组成氨基酸或者接合至末端氨基酸的α碳氨基和羧基。通常,衍生化所述抗体或其部分使得与靶抗原的结合不受所述衍生化或标记的不利影响。
在某些情况中,当所述免疫缀合物已经到达其靶位点时,需要从所述抗体释放所述效应分子。因此,在这些情况中,免疫缀合物会包含所述靶位点附近可切割的键。切割所述接头以将所述效应分子从所述抗体释放可以由酶活性引起,或由所述免疫缀合物在所述靶细胞内或靶位点附近所处的条件引起。
本发明另一目的在于提供一种多核苷酸,编码本发明所述的抗体,重组蛋白或者免疫缀合物。
本发明另一目的在于提供一种载体,含有本发明所述的多核苷酸。所述的载体包括:细菌质粒、噬菌体、酵母质粒、植物细胞病毒、哺乳动物细胞病毒如腺病毒、逆转录病毒或其他载体。
本发明另一目的在于提供一种药物组合物,包括本发明所述的抗体或其抗原结合片段、重组蛋白、双特异性抗体、免疫缀合物、多核苷酸、载体或遗传工程化的宿主细胞中的一种或几种。所述药物组合物还包括药学上可接受的载体。所述抗体、重组蛋白、双特异性抗体、免疫缀合物、多核苷酸、载体或遗传工程化的宿主细胞可溶于水性载体,例如缓冲盐水等。还可以含有接近生理条件所需要的可药用辅料,例如pH调节剂和缓冲试剂等,乙酸钠、氯化钠、氯化钾、氯化钙或乳酸钠等。
本发明所述的药物或药物组合物可以与GITR、CD137、PD-1、PD-Ll、OX40、CTLA4、TIGIT、LAG3、CD47、SIRPa免疫检查点抑制剂中的一种或几种形成药物组合物。所述的药物或药物组合物还进一步包括药学上可接受的载体、赋形剂和/或稀释剂。
本发明另一目的在于提供本发明所述的抗体或其抗原结合片段、重组蛋白、免疫缀合物、多核苷酸、载体或遗传工程化的宿主细胞在制备自身免疫疾病、病毒感染或癌症的治疗药物或诊断试剂中的应用。
所述癌症为肝癌、胃癌、结直肠癌、肺癌、卵巢癌,或表达LAG3的任何其他类型的癌症。
本发明公开的单克隆抗体或其抗原结合片段还可用于制备嵌合抗原受体(CAR;也称为嵌合T细胞受体、人造T细胞受体或嵌合免疫受体)或双特异性抗体。
本发明所述的药物或约物组合物还可以包括激活的或未激活的T细胞、经过遗传修饰的T细胞、经过体外诱导、激活与培养的人淋巴细胞。
本发明还提供了一种检测试剂、诊断试剂或诊断试剂盒包含本发明所述的抗体或抗原结合片段、双特异性抗体或融合蛋白、免疫偶联物、核酸分子或载体中的一种或几种,利用其检测生物样本中是否存在LAG3蛋白和/或检测LAG3蛋白的含量。
本发明具体实施例中公开了高亲和力的LAG3单克隆抗体。本发明还公开了该抗体体外活性以及联合hYP7-OKT3双特性抗体(T细胞型双特异性抗体在肝癌和小细胞肺癌中的抗肿瘤活性研究,陈鑫,2020,华中农业大学博士学位论文)治疗肝癌的效果。所述的抗体和组合物可以用于治疗LAG3表达阳性的肿瘤。
本发明所提供的抗体和组合物可用于多种目的,例如用于肿瘤的分子诊断。所述样品可以为任何样品,包括但不限于来自活组织检查、尸体解剖和病理标本的组织。生物样品还包括组织的切片,例如为组织学目的获取的冷冻切片。生物样品还包括体液,例如血液、血清、血浆、痰、脊髓液或尿。生物样品一般获自哺乳动物,包括人,非人灵长类,小鼠等。
本发明优点:
本发明所提供的单克隆抗体不仅亲和力高(Kd值均在nM和pM级,甚至更高),而且热稳定性好。本发明所提供的单克隆抗体能够以高活性阻断LAG3与其配体MHC-II或FGL1的相互作用。本发明所提供的单克隆抗体与双特异性抗体或PD1抗体联用可以明显增强单药抗肿瘤活性。
附图说明
图1.本发明所述LAG3单克隆抗体M234 scFv-HF与LAG3ECD-hFc亲和力测定。
图2.本发明所述LAG3单克隆抗体M234 scFv-HF与LAG3D1D2-hFc亲和力测定。
图3.本发明所述M234 IgG与Bio-LAG3D1D2-hFc亲和力测定。
图4.本发明所述M234 IgG结合激活的PBMC细胞。
图5.Bio-LAG3D1D2-hFc与FGL1-hFc亲和力。
图6.本发明所述M234 IgG阻断BioLAG3D1D2-hFc与FGL1-hFc结合的能力。
图7.M234 IgG阻断BioLAG3D1D2-hFc与Raji细胞表面MHC-II互作。
图8.M234 IgG抑制Huh-7肿瘤细胞在NOD-SCID小鼠体内的生长。
图9.M234 IgG治疗Huh7荷瘤小鼠后的体重变化。
图10.人源化M234单克隆抗体的亲和力检测。
具体实施方式
本发明公开描述了结合LAG3的单克隆抗体的制备和鉴定。具体的实施方案公开了靶向LAG3单克隆抗体的分离和表征。
下面结合具体实施例并参照数据进一步详细描述本发明,应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。在本发明中使用的术语,除非另有说明,一般具有本领域普通技术人员通常理解的含义。在以下实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
缩写
CDR互补决定区
CTL细胞毒性T淋巴细胞
ELISA酶联免疫吸附测定
FACS荧光激活细胞分选
GPC3磷脂酰肌醇蛋白聚糖3
BLI 生物膜干涉技术
HCC 肝细胞癌
hFc人Fc
Ig免疫球蛋白
mAb单克隆抗体
PE藻红蛋白
实施例1本发明所述LAG3的单克隆抗体的制备
本实施例描述了针对肿瘤相关LAG3的高亲和力单克隆抗体的制备。
使用293F细胞表达、纯化LAG3ECD和LAG3D1D2融合hFc的截短蛋白(截短信息参考NP_002277.4)。以LAG3ECD-hFc和LAG3D1D2-hFc蛋白免疫6周龄小鼠,每次免疫50μg,每次间隔3周,免疫2次之后采集小鼠的脾脏,提取脾脏中的总RNA,逆转录为cDNA,作为建立噬菌体抗体文库的模板,并构建小鼠抗体噬菌体文库(库容量4.6×109)。利用LAG3ECD-hFc蛋白作为抗原,对噬菌体文库进行3次淘选后,随机挑取单个克隆进行测序,获得高亲和力LAG3单克隆抗体M234。
抗体M234互补决定区(CDR区)以及可变区氨基酸序列如表1和2所示:
表1.LAG3 M234单克隆抗体的CDR氨基酸序列(根据Kabat和IMGT)
表2.LAG3M234单克隆抗体的可变区氨基酸序列
实施例2本发明所述LAG3的单克隆抗体M234 scFv-HF对LAG3蛋白亲和力
使用HB2151原核表达实施例1的单克隆抗体scFv-HF,表达产物用Ni-NTA层析柱(GE healthcare)进行纯化。利用ELISA法对抗体亲和力进行检测。
首先将LAG3ECD-hFc蛋白或LAG3D1D2-hFc蛋白分别包被在ELISA板底,随后分别加入上述制得的M234 scFv-HF,首孔200nM,1:3梯度稀释,与之孵育,使用HRP标记的山羊抗FLAG抗体作为二抗进行检测。使用TMB显色液显色后用多功能酶标仪检测吸光度,最后使用GraphPad Prism分析结果。结果如图1和图2所示,M234与LAG3ECD-hFc和LAG3D1D2-hFc亲和力分别为0.2nM和0.14nM。
实施例3本发明所述M234 IgG对LAG3蛋白的亲和力
将实施例1得到的抗体M234重链可变区连接IgG1型抗体的重链恒定区,轻链可变区连接轻链恒定区后分别构建到有两启动子的IgG表达载体上,使用293F细胞进行表达,表达产物用ProteinA层析柱(GE healthcare)进行纯化。利用ELISA法对抗体亲和力进行检测。
首先将M234 IgG蛋白分别包被在ELISA板底,同时使用NHS-Biotin(生工生物)冰上标记LAG3D1D2-hFc蛋白,得到生物素标记的Bio-LAG3D1D2。随后将生物素标记的BioLAG3D1D2-hFc以首孔200nM 1:3梯度稀释,与之孵育,使用HRP标记的链霉亲和素作为二抗进行检测。使用TMB显色液显色后用多功能酶标仪检测吸光度,最后使用GraphPad Prism分析结果。结果如图3所示,BioLAG3D1D2-hFc与M234单克隆抗体亲和力为0.45nM。
实施例4M234 IgG稳定性的检测
Tm值是定量描述蛋白的热稳定性的参数,是成药性评价中最为常用的指标之一。Tm值越高意味着蛋白构象越稳定。利用Nano Temper公司的Prometheus NT.48测定实施例1制得的抗体的稳定性:将抗体浓度稀释成500μg/ml,然后上样,1℃/min的速度,从25℃上升到95℃。最后得出抗体的Tm值。结果如表3所示,抗体M234的Tm1为61.67℃,Tm2为87.73℃,聚集温度为89.12℃,M234的热稳定性和聚集性均强于已上市的LAG3单克隆抗体Relatlimab。
表3本发明所述单克隆抗体的Tm值
实施例4FACS检测本发明所述M234 IgG与LAG3阳性细胞系的结合
将PBMC细胞用CD3Ab/CD28Ab和IL-2激活后使用1640培养基(Invitrogen,Carlsbad,CA)添加10%胎牛血清(HyClone,Logan,UT)、1%L-谷氨酰胺和1%青霉素-链霉素(Invitrogen,Carlsbad,CA)进行培养。收获细胞后,将实施例3制得的抗体与激活的PBMC细胞进行结合,加入PE标记的羊抗人Fc二抗,检测结合至细胞表面上的抗体。结果如图4所示,实施例3制得的M234与PBMC细胞亲和力为0.10nM。
实施例5本发明所述M234 IgG阻断LAG3与FGL1的结合
首先将FGL1包被在ELISA板底,同时使用NHS-Biotin(生工生物)冰上标记LAG3D1D2-hFc蛋白,得到生物素标记的Bio-LAG3D1D2。Bio-LAG3D1D2以1:2的稀释度从1000nM开始稀释,加入ELISA板底后37℃孵育30min,使用HRP标记的链霉亲和素作为二抗进行检测。使用TMB显色液显色后用多功能酶标仪检测吸光度,最后使用GraphPad Prism分析结果。结果显示LAG3-FGL1亲和力如图5所示。
抗体阻断实验首先将FGL1包被ELISA板底,然后首孔200nM 1:3梯度稀释分别将实施例3制得的M234 IgG与100nM BioLAG3D1D2共孵育30min后加入ELISA板中,用HRP标记的链霉亲和素作为二抗进行检测。使用TMB显色液显色后用多功能酶标仪检测吸光度,最后使用GraphPad Prism分析结果。抗体阻断活性如图6所示,结果显示抗体M234具有LAG3-FGL1阻断活性,IC50为15nM。
实施例6本发明所述M234 IgG阻断LAG3与MHC-II的结合
Raji细胞天然高表达MHC-II,阻断实验使用Raji细胞。使用1640培养基(Invitrogen,Carlsbad,CA)添加10%胎牛血清(HyClone,Logan,UT)、1%L-谷氨酰胺和1%青霉素-链霉素(Invitrogen,Carlsbad,CA)进行Raji细胞的培养。10μg/ml LAG3ECD-hFc蛋白与梯度稀释的实施例3制得的抗体M234 IgG共孵育30min,然后加入收集到的Raji细胞中冰上孵育30min。最后加入PE标记的羊抗人二抗,检测结合至细胞表面上的抗体。结果如图7所示,抗体M234具有LAG3-MHC-II阻断活性,其阻断IC50为6.2nM。
实施例7M234 IgG在小鼠体内抑制肿瘤的生长
选择肝癌细胞系Huh-7作为抗体抑瘤活性的测试细胞。Huh-7细胞使用DMEM培养基(Invitrogen,Carlsbad,CA)添加10%胎牛血清(HyClone,Logan,UT)、1%L-谷氨酰胺和1%青霉素-链霉素(Invitrogen,Carlsbad,CA)进行培养。细胞消化后每只小鼠注射5×106个细胞,待到成瘤后,每只小鼠注射5×106个PBMC细胞,以0.2mg/kg hYP7-OKT3双特异抗体(抗体制备过程参考陈鑫博士的博士学位论文(T细胞型双特异性抗体在肝癌和小细胞肺癌中的抗肿瘤活性研究,华中农业大学,2020))联合10mg/kg实施例3制备的LAG3单克隆抗体进行免疫治疗。小鼠肿瘤生长曲线如图8和表4所示,体重变化如图9所示。结果显示本发明所述的M234 IgG单克隆抗体联合双特异性抗体可以显著增强抗肿瘤活性。
表4小鼠肿瘤体积
实施例8M234的人源化及人源化M234 IgG的亲和力检测
将单克隆抗体M234使用人源抗体Germline骨架替换的方法进行人源化改造,得到人源化Hu1M234的序列,对人源化M234的重链进行回复突变得到Hu2M234,对人源化M234的轻链回复突变得到Hu3M234,轻链和重链同时回复突变得到Hu4M234,人源化序列如表5所示。
将人源化M234的重链可变区连接人源IgG1型抗体的重链恒定区并在Fc区后添加Flag标签,将人源化M234的轻链可变区连接人源抗体κ轻链恒定区,然后分别克隆到IgG表达载体上,构建IgG表达质粒,并使用293F细胞进行表达,表达产物用ProteinA层析柱(GEhealthcare)进行纯化。利用ELISA方法对HuM234 IgG的亲和力进行检测。
表5人源化M234的VH和VL序列
首先将LAG3ECD-hFc蛋白包被在ELISA板底,随后加入人源化的M234 IgG-Flag抗体,首孔200nM,其余各孔浓度按照1:3梯度稀释,与包被的LAG3ECD蛋白孵育,然后使用HRP标记的FLAG抗体进行检测,使用TMB显色液显色后用多功能酶标仪检测吸光度,最后使用GraphPad Prism分析实验结果。结果如图10所示,人源化的HuM234 IgG亲和力分别为0.96nM,0.52nM,0.59nM,0.16nM,其中Hu4M234亲和力与原始M234抗体亲和力基本一致。
Claims (17)
1.靶向人淋巴细胞激活基因3的单克隆抗体或其抗原结合片段,包括重链可变区和轻链可变区,其特征在于:
所述单克隆抗体或其抗原结合片段包括SEQ ID NO:1所示的重链可变区CDR1、SEQ IDNO:2所示的重链可变区CDR2、SEQ ID NO:3所示的重链可变区CDR3,SEQ ID NO:4所示的轻链可变区CDR1、SEQ ID NO:5所示的轻链可变区CDR2、SEQ ID NO:6所示的轻链可变区CDR3。
2.根据权利要求1所述的单克隆抗体或其抗原结合片段,其特征在于:
(1)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:7所示,轻链可变区氨基酸序列如SEQ ID NO:8所示;
或者,(2)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:9所示,轻链可变区氨基酸序列如SEQ ID NO:10所示。
或者,(3)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:11所示,轻链可变区氨基酸序列如SEQ ID NO:12所示。
或者,(4)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:13所示,轻链可变区氨基酸序列如SEQ ID NO:14所示。
或者,(5)所述抗体或其抗原结合片段的重链可变区氨基酸序列如SEQ ID NO:15所示,轻链可变区氨基酸序列如SEQ ID NO:16所示。
3.根据权利要求1所述的单克隆抗体或其抗原结合片段,其特征在于所述抗体是单链抗体、双链抗体、嵌合抗体或人源化抗体。
4.根据权利要求1所述的单克隆抗体或其抗原结合片段,其特征在于所述抗体是VH单结构域抗体、Fab片段、Fab'片段、F(ab)'2片段、单链可变片段scFv或二硫键稳定的可变片段dsFv。
5.一种重组蛋白,其特征在于,所述的重组蛋白包括权利要求1-4任一项所述的单克隆抗体或其抗原结合片段和协助表达和/或纯化的标签序列。
6.双特异性抗体或融合蛋白,其特征在于所述双特异性抗体或融合蛋白含有权利要求1-4任一项所述的单克隆抗体或其抗原结合片段或者含有权利要求5所述的重组蛋白。
7.免疫偶联物,其特征在于所述免疫偶联物含有权利要求1-4任一项所述的单克隆抗体或其抗原结合片段、权利要求5所述的重组蛋白或含有权利要求6所述的双特异性抗体或融合蛋白。
8.根据权利要求7所述的免疫偶联物,其特征在于所述免疫偶联物的效应分子选自荧光标签放射性标记, 亲和素, 生物素, 酶、毒素或化疗剂中的一种或几种。
9.一种多核苷酸, 其特征在于其编码根据权利要求1-4任一项所述的抗体或其抗原结合片段,或权利要求5所述的重组蛋白, 或权利要求6所述的双特异性抗体或融合蛋白, 或者权利要求7或8所述的免疫缀合物。
10.一种载体, 其特征在于含有权利要求9所述的多核苷酸。
11.权利要求1-4任一项所述的单克隆抗体或其抗原结合片段、权利要求5所述的重组蛋白、权利要求6所述的双特异性抗体或融合蛋白、权利要求7或8所述的免疫偶联物、权利要求9所述的多核苷酸或者权利要求10所述的载体在制备免疫检查点抑制剂中的应用。
12.根据权利要求11所述的应用, 其特征在于所述免疫检查点抑制剂为诊断或治疗免疫性疾病、慢性病毒感染或肿瘤的试剂或药物。
13.一种药物组合物, 其特征在于所述约物组合物包含权利要求1 - 4所述的单克隆抗体或其抗原结合片段、权利要求5所述的重组蛋白、权利要求6所述的双特异性抗体或融合蛋白、权利要求7或8所述的免疫偶联物、权利要求9所述的多核苷酸或权利要求10所述的载体中的一种或几种。
14.根据权利要求13所述的药物组合物, 其特征在于所述药物组合物还包括GITR、CD137、PD- 1、PD- L1、OX40、CTLA4、TI GIT、LAG3、CD47、SIRPa免疫检查点抑制剂中的一种或几种。
15.根据权利要求13所述的药物组合物, 其特征在于所述药物组合物还包括激活的或未激活的T细胞、经过遗传修饰的T细胞或者经过体外诱导、激活与培养的人淋巴细胞中的一种或几种。
16.宿主细胞, 其特征在于所述宿主细胞携带权利要求9所述的多核苷酸或权利要求10所述的载体。
17.LAG-3蛋白检测试剂、诊断试剂或诊断试剂盒, 其特征在于包含权利要求1-4所述的单克隆抗体或其抗原结合片段、权利要求5或6所述的双特异性抗体和融合蛋白、权利要求7或8所述的免疫偶联物、权利要求9所述的核酸分子或权利要求10所述的载体中的一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410287305.9A CN118221816A (zh) | 2024-03-13 | 2024-03-13 | Lag3单克隆抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410287305.9A CN118221816A (zh) | 2024-03-13 | 2024-03-13 | Lag3单克隆抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118221816A true CN118221816A (zh) | 2024-06-21 |
Family
ID=91503290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410287305.9A Pending CN118221816A (zh) | 2024-03-13 | 2024-03-13 | Lag3单克隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118221816A (zh) |
-
2024
- 2024-03-13 CN CN202410287305.9A patent/CN118221816A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105579471B (zh) | 结合人程序性死亡配体1(pd-l1)的抗体 | |
JP5941615B2 (ja) | ヒトcxcl1タンパク質の免疫学的測定方法 | |
CN109988240B (zh) | 抗gpc-3抗体及其用途 | |
CN110382533B (zh) | 特异性结合CD66c的抗体及其用途 | |
US9738726B2 (en) | HER2-specific monoclonal antibodies and conjugates thereof | |
CN114539411B (zh) | 一种ror1抗体或其抗原结合片段 | |
JP2022516848A (ja) | Btn3a結合タンパク質及びその使用 | |
CN114671953B (zh) | 单域抗Nectin-4抗体 | |
CN114702589B (zh) | 治疗癌症的组合物和方法 | |
CN112094348A (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
CN113637077B (zh) | 一种抗mica的抗体及其应用 | |
KR20220024211A (ko) | 항-cd47 항체 및 그것의 사용 | |
WO2021121373A1 (zh) | 抗人程序死亡因子-1单克隆抗体 | |
CN115667304A (zh) | 抗人lag-3抗体及其在免疫组织化学(ihc)中的用途 | |
WO2023219147A1 (ja) | Ccr8検出用新規抗ccr8抗体 | |
CN109810194B (zh) | 抗dr5的抗体及其制备方法和应用 | |
CN110938146A (zh) | Tim-3单域抗体及其应用 | |
CN118221816A (zh) | Lag3单克隆抗体及其应用 | |
CN117586397A (zh) | 抗人cd147的单克隆抗体、表达载体、细胞株及其应用 | |
KR20120134547A (ko) | 항-atic 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
CN113880948B (zh) | 抗ca724抗体或其抗原结合片段及其制备方法和应用 | |
CN110615841B (zh) | 抗人cd47单克隆抗体及其应用 | |
CN115843256A (zh) | 抗erbb3抗体或其抗原结合片段及其医药用途 | |
CN116836291B (zh) | 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用 | |
CN116063536B (zh) | 抗人MxA单克隆抗体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |